TooNiceStocks Initiates Coverage on BioSante Pharmaceuticals, Inc. Looming February 14th, 2012 FDA Decision with Elevated Interest

BioSante Pharmaceuticals is a development stage biotech company focusing on drugs for sexual health and oncology. TooNiceStocks research discovered the recent collapse in the company’s stock on December 14, 2011 from the day’s high of 2.60 to a low of 0.38 in after hours trading, have left many investors asking, "so what’s next for BioSante?" Since then, BioSante has slowly recovered somewhat, the stock is still trading at a much-reduced range of $.50, a substantial discount of roughly $52 million market cap compared to about $286 million before the news. However with one drug approved and another facing a regulatory decision in the form of a PDUFA on February 14th, 2012, smallcap investors are already gambling.

(PRWeb January 13, 2012)

Read the full story at

Editorials Commend FDA Decision To Expand Access To Plan B Emergency Contraception

Two newspapers recently published editorials responding to the FDA’s decision to lower the age limit for nonprescription sale of the emergency contraceptive Plan B from age 18 to age 17. Summaries appear below.~